Use of selected reaction monitoring mass spectrometry for the detection of specific MHC class I peptide antigens on A3 supertype family members

Cancer Immunology, Immunotherapy : CII
Kevin T HoganC L Slingluff

Abstract

The development of peptide-based vaccines that are useful in the therapeutic treatment of melanoma and other cancers ultimately requires the identification of a sufficient number of antigenic peptides so that most individuals, regardless of their major histocompatibility complex (MHC)-encoded class I molecule phenotype, can develop a cytotoxic T lymphocyte (CTL) response against one or more peptide components of the vaccine. While it is relatively easy to identify antigenic peptides that are presented by the most prevalent MHC class I molecules in the population, it is problematic to identify antigenic peptides that are presented by MHC class I molecules that have less frequent expression in the population. One manner in which this problem can be overcome is by taking advantage of known MHC class I supertypes, which are groupings of MHC class I molecules that bind peptides sharing a common motif. We have developed a mass spectrometric approach which can be used to determine if an antigenic peptide is naturally processed and presented by any given MHC class I molecule. This approach has been applied to the A3 supertype, and the results demonstrate that some, but not all, A3 supertype family-associated peptides can associate with...Continue Reading

References

Jan 1, 1982·Hybridoma·A E BergerP Cresswell
Aug 1, 1982·Human Immunology·S A EllisA McMichael
Feb 1, 1994·Current Opinion in Immunology·V H Engelhard
Jan 1, 1994·Annual Review of Immunology·V H Engelhard
Apr 26, 1994·Proceedings of the National Academy of Sciences of the United States of America·Y KawakamiS A Rosenberg
Dec 5, 1995·Proceedings of the National Academy of Sciences of the United States of America·U SahinM Pfreundschuh
Dec 1, 1996·The Journal of Experimental Medicine·R F WangS A Rosenberg
Mar 4, 1997·Proceedings of the National Academy of Sciences of the United States of America·Y T ChenL J Old
Sep 2, 1998·Current Opinion in Immunology·A Sette, J Sidney
Nov 24, 1999·Immunological Reviews·R F Wang, S A Rosenberg
Jun 8, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·V L CrotzerV H Engelhard
Apr 24, 2001·Cancer Immunology, Immunotherapy : CII·N RenkvistG Parmiani
Jul 7, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·E KeoghA Sette
Feb 28, 2002·Annual Review of Immunology·Nilabh ShastriThomas Serwold

❮ Previous
Next ❯

Citations

Sep 22, 2010·Melanoma Research·Leann M MikeshCraig L Slingluff
Nov 12, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Craig L SlingluffKimberly A Chianese-Bullock
Jan 24, 2008·BMC Immunology·John SidneyAlessandro Sette
Feb 6, 2013·PLoS Pathogens·Nathan P CroftAnthony W Purcell
Apr 24, 2014·Cancer Immunology, Immunotherapy : CII·Yinin HuCraig L Slingluff
May 21, 2011·Proteomics·Chor Teck TanAnthony W Purcell
Apr 10, 2016·Current Opinion in Immunology·Anthony W PurcellDavid C Tscharke
May 8, 2016·Current Opinion in Immunology·Michal Bassani-Sternberg, George Coukos
Sep 14, 2016·Oncoimmunology·David GfellerImmanuel F Luescher
Apr 15, 2017·The Cancer Journal·Moreno Di MarcoHans-Georg Rammensee
Apr 26, 2018·Expert Review of Proteomics·Deepali RathoreSarah Rogstad
Aug 1, 2007·Proteomics. Clinical Applications·Richard R DrakeO John Semmes
Nov 1, 2007·Clinical Pharmacology and Therapeutics·I G OvsyannikovaG A Poland
Dec 3, 2015·Molecular & Cellular Proteomics : MCP·Etienne CaronRuedi Aebersold
Nov 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Craig L SlingluffPatrice K Rehm
May 23, 2021·Molecular & Cellular Proteomics : MCP·Arie Admon
Sep 10, 2021·Proceedings of the National Academy of Sciences of the United States of America·Lauren E StopferForest M White

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.